1
|
Mihaylova V, Herenger Y, Bethge T, Bohlhalter S. A Novel WARS2 Mutation in a Swiss Family With Predominant Generalized Dystonia Responsive to Trihexyphenidyl. J Clin Neurol 2023; 19:413-415. [PMID: 37417438 DOI: 10.3988/jcn.2022.0410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 01/30/2023] [Accepted: 03/07/2023] [Indexed: 07/08/2023] Open
Affiliation(s)
| | - Yvan Herenger
- Genetica AG, Zurich, Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Tobias Bethge
- Genetica AG, Zurich, Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | | |
Collapse
|
2
|
Condoluci A, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M, Bacher U, Bode P, Cavalli A, Dirnhofer S, Djerbi N, Dobner S, Fehr T, Garofalo M, Gaspert A, Gerull S, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Magini G, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pabst T, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Treglia G, Tzankov A, Vetter F, Zweier M, Flammer AJ, Gerber B. Management of transthyretin amyloidosis. Swiss Med Wkly 2021; 151:w30053. [PMID: 34694105 DOI: 10.4414/smw.2021.w30053] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity of ATTR amyloidosis and the variable presentation of symptoms at early disease stages, historically meant treatment delays. Diagnostic tools and therapy options of ATTR amyloidosis have markedly improved in recent years. The first Swiss Amyloidosis Network (SAN) meeting (Zurich, Switzerland, January 2020) aimed to define a consensus statement regarding the diagnostic work-up and treatment for systemic amyloidosis, tailored to the Swiss healthcare system. A consortium of 45 clinicians and researchers from all Swiss regions and universities was selected by the SAN committee to represent all sub-specialty groups involved in care of patients with amyloidosis. A steering committee conducted the literature search and analysis, wrote the critical synthesis and elaborated a list of statements that were evaluated by all the participants. These recommendations will improve outcomes and quality of life for patients with ATTR amyloidosis. A global review of these guidelines is planned every 3 years with a formal meeting of all the involved experts.
Collapse
Affiliation(s)
- Adalgisa Condoluci
- Division of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Marie Théaudin
- Department of Neurology, Neuromuscular Unit, University Hospital and University of Lausanne, Switzerland
| | - Rahel Schwotzer
- Department of Medical Oncology and Haematology, University Hospital of Zurich, Switzerland
| | - Aju P Pazhenkottil
- Department of Cardiology, University Heart Centre, University Hospital and University Zurich, Switzerland.,Cardiac Imaging, Department of Nuclear Medicine, University Hospital and University of Zurich, Switzerland
| | - Paolo Arosio
- Department of Chemistry and Applied Biosciences, ETHZ, Zurich, Switzerland
| | | | - Ulrike Bacher
- Department of Haematology, Inselspital, University Hospital and University of Bern, Switzerland
| | - Peter Bode
- Department of Pathology and Molecular Pathology, University Hospital and University of Zurich, Switzerland
| | - Andrea Cavalli
- Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.,Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Stefan Dirnhofer
- Department of Medical Genetics and Pathology, University Hospital and University of Basel, Switzerland
| | - Nadia Djerbi
- Department of Medical Oncology and Haematology, University Hospital of Zurich, Switzerland
| | - Stephan Dobner
- Department of Cardiology, Inselspital, University Hospital and University of Bern, Switzerland
| | - Thomas Fehr
- Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland
| | - Maura Garofalo
- Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland
| | - Ariana Gaspert
- Department of Pathology and Molecular Pathology, University Hospital and University of Zurich, Switzerland
| | - Sabine Gerull
- Department of Hematology, Cantonal Hospital Aarau, Switzerland
| | - Raphael Heimgartner
- Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland
| | - Annemarie Hübers
- Department of Neurology, University Hospital and University of Geneva, Switzerland
| | - Hans H Jung
- Department of Neurology, University Hospital and University Zurich, Switzerland
| | - Chiara Kessler
- Division of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Raphael Knöpfel
- Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland
| | - Natallia Laptseva
- Department of Cardiology, University Heart Centre, University Hospital and University Zurich, Switzerland
| | - Giulia Magini
- Service de Transplantation, Hôpitaux Universitaires de Genève, Geneva, Switzerland
| | - Robert Manka
- Department of Cardiology, University Heart Centre, University Hospital and University Zurich, Switzerland.,Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich,Switzerland
| | | | - Martin Meyer
- Department of Cardiology, University Heart Centre, University Hospital and University Zurich, Switzerland
| | - Violeta Mihaylova
- Department of Neurology, University Hospital and University Zurich, Switzerland
| | - Pierre Monney
- Department of Cardiology, University Hospital and University of Lausanne, Switzerland
| | - Alessio Mylonas
- Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - René Nkoulou
- Department of Cardiology, University Hospital and University of Geneva, Switzerland
| | - Thomas Pabst
- Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Switzerland
| | - Otmar Pfister
- Department of Cardiology, University Hospital and University of Basel, Switzerland
| | - Axel Rüfer
- Department of Haematology, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Adrian Schmidt
- Department of Internal Medicine, Clinic for Medical Oncology and Haematology, City Hospital Waid and Triemli, Zurich, Switzerland
| | - Harald Seeger
- Department of Nephrology, University Hospital and University Zurich, Switzerland
| | - Simon F Stämpfli
- Department of Cardiology, Heart Centre Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Guido Stirnimann
- University Clinic for Visceral Surgery and Medicine, University Hospital Inselspital and University of Bern, Switzerland
| | - Thomas Suter
- Department of Cardiology, Inselspital, University Hospital and University of Bern, Switzerland
| | - Giorgio Treglia
- Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.,Department of Nuclear Medicine and Molecular Imaging, University Hospital and University of Lausanne, Switzerland.,Faculty of Biomedical sciences, Università della Svizzera Italiana, Lugano, Switzerland
| | - Alexandar Tzankov
- Department of Medical Genetics and Pathology, University Hospital and University of Basel, Switzerland
| | - Friederike Vetter
- Department of Medical Oncology and Haematology, University Hospital of Zurich, Switzerland
| | - Markus Zweier
- Institute of Medical Genetics, University of Zurich, Switzerland
| | - Andreas J Flammer
- Department of Cardiology, University Heart Centre, University Hospital and University Zurich, Switzerland
| | - Bernhard Gerber
- Division of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.,University of Zurich, Switzerland
| |
Collapse
|
3
|
Mihaylova V, Chablais F, Bremer J, Guggenberger R, Rushing EJ, Bethge T, Spiegel R, Jung HH. Collagen VI-Related Myopathy Caused by Compound Heterozygous Mutations of COL6A3 in a Consanguineous Kurdish Family. J Clin Neuromuscul Dis 2021; 22:173-179. [PMID: 33596003 DOI: 10.1097/cnd.0000000000000320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
ABSTRACT Collagen VI-related myopathies are caused by mutations of COL6A1, COL6A2, and COL6A3 and present with a wide phenotypic spectrum ranging from severe Ulrich congenital muscular dystrophy to mild Bethlem myopathy. Here, we report a consanguineous Kurdish family with 3 siblings affected by autosomal-recessive Bethlem myopathy caused by compound heterozygous mutations of COL6A3. We found the previously described missense mutation c.7447A > G/p.(Lys2483Glu) and a novel large deletion encompassing the exon 1-39 of the COL6A3 gene. Apart from the classical clinical symptoms, all patients had keratoconus, which expands the phenotype of the collagen VI-related myopathies.
Collapse
Affiliation(s)
- Violeta Mihaylova
- Department of Neurology, University Hospital and University of Zurich, Zürich, Switzerland
| | - Fabian Chablais
- Genetica, Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Juliane Bremer
- Institute of Neuropathology, University Hospital and University of Zurich, Zürich, Switzerland
- Institute of Neuropathology, University Hospital RWTH Aachen, Aachen, Germany ; and
| | - Roman Guggenberger
- Department of Radiology, University Hospital and University of Zurich, Zürich, Switzerland
| | - Elisabeth J Rushing
- Institute of Neuropathology, University Hospital and University of Zurich, Zürich, Switzerland
| | - Tobias Bethge
- Genetica, Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Roland Spiegel
- Genetica, Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Hans-Heinrich Jung
- Department of Neurology, University Hospital and University of Zurich, Zürich, Switzerland
| |
Collapse
|
4
|
Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly 2020; 150:w20364. [PMID: 33277911 DOI: 10.4414/smw.2020.20364] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into insoluble beta-sheet rich structures that deposit extracellularly in different organs, eventually compromising their function. There are more than 30 different proteins, known to be amyloidogenic with “light chain” (AL)-amyloidosis being the most common type, followed by transthyretin (ATTR)-, and amyloid protein A (AA)-amyloidosis. Systemic amyloidosis is a rare disease with an incidence of around 10 patients in 1 million inhabitants. Recently several new therapeutic options have been developed for subgroups of amyloidosis patients, and the introduction of novel therapies for plasma cell myeloma has led to an increase in the therapeutic armamentarium for plasma cell disorders, including AL amyloidosis. Among them, proteasome inhibitors, immunomodulatory agents (-imids), and monoclonal antibodies have been successfully introduced into clinical practice. Still, high-quality data from randomised controlled trials regarding the benefit of these cost-intensive drugs in AL amyloidosis are widely lacking, and due to the rarity of the disease many physicians will not gain routine experience in the management of these frail patients. The diagnosis of AL amyloidosis relies on a close collaboration between clinicians, pathologists, imaging experts, and sometimes geneticists. Diagnosis and treatment options in this complex disorder should be discussed in dedicated multidisciplinary boards. In January 2020, the first meeting of the Swiss Amyloidosis Network took place in Zurich, Switzerland. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system. Forty-five participants from different fields in medicine discussed many aspects of amyloidosis. These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis.
Collapse
Affiliation(s)
- Rahel Schwotzer
- Department of Medical Oncology and Haematology, University Hospital Zurich, Switzerland
| | | | - Sabine Gerull
- Department of Hematology, University Hospital Basel, Basel, Switzerland
| | - Thomas Pabst
- Department of Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland
| | - Paolo Arosio
- Departement of Chemistry and Applied Biosciences. 'ETHZ', Zurich, Switzerland
| | | | - Vera Ulrike Bacher
- Department of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland
| | - Peter Bode
- Departement of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Andrea Cavalli
- Institute of Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland / Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Adalgisa Concoluci
- Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Stefan Dirnhofer
- Departement of Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland
| | - Nadia Djerbi
- Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
| | - Stefan W Dobner
- Departement of Cardiology, Inselspital, University Hospital of Bern, Bern, Switzerland
| | - Thomas Fehr
- Departement of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland
| | - Maura Garofalo
- Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland
| | - Ariana Gaspert
- Departement of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Raphael Heimgartner
- Departement of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland
| | - Annemarie Hübers
- Departement of Neurology, University Hospital of Geneva, Geneva, Switzerland
| | - Hans H Jung
- Departement of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
| | - Chiara Kessler
- Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Raphael Knöpfel
- Departement of Internal Medicine, Hospital Thusis, Thusis, Switzerland
| | - Natallia Laptseva
- Departement of Cardiology, University Hospital Zurich, Zurich, Switzerland
| | - Robert Manka
- Department of Cardiology, University Hospital, Zurich, Switzerland / Departement of Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland
| | | | - Martin Meyer
- Department of Cardiology, University Hospital, Zurich, Switzerland
| | - Violeta Mihaylova
- Department of Neurology, University Hospital and University Zurich, Zurich, Switzerland
| | - Pierre Monney
- Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Alessio Mylonas
- Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - René Nkoulou
- Department of Cardiology, University Hospital and University of Geneva, Geneva, Switzerland
| | - Aju Pazhenkottil
- Department of Cardiology, University Hospital, Zurich, Switzerland
| | - Otmar Pfister
- Department of Cardiology, University Hospital and University of Basel, Basel, Switzerland
| | - Axel Rüfer
- Department of Hematology, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Adrian Schmidt
- Department of Internal Medicine, Clinic for Medical Oncology and Hematology, City Hospital Waid and Triemli, Zurich, Switzerland
| | - Harald Seeger
- Department of Nephrology, University Hospital and University Zurich, Zurich, Switzerland
| | - Simon F Stämpfli
- Department of Cardiology, Heart Centre Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Guido Stirnimann
- University Clinic for Visceral Surgery and Medicine, University Hospital Inselspital and University of Bern, Bern, Switzerland
| | - Thomas Suter
- Department of Cardiology, Inselspital, University Hospital and University of Bern, Bern, Switzerland
| | - Marie Théaudin
- Department of Neurology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Giorgio Treglia
- Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland / Department of Nuclear Medicine and Molecular Imaging, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Alexandar Tzankov
- Department of Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland
| | - Friederike Vetter
- Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
| | - Markus Zweier
- Institute of Medical Genetics, University of Zurich, Zurich, Switzerland
| | - Bernhard Gerber
- Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| |
Collapse
|
5
|
Mihaylova V, Chablais F, Herenger Y, Spiegel R, Heinrich Jung H. Novel truncating mutations of MYO18B causing congenital myopathy in a Swiss patient. Neurol Genet 2020; 6:e458. [PMID: 32637634 PMCID: PMC7323478 DOI: 10.1212/nxg.0000000000000458] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Accepted: 05/14/2020] [Indexed: 11/15/2022]
Affiliation(s)
- Violeta Mihaylova
- Department of Neurology (V.M., H.H.J.), University Hospital and University of Zurich; and Genetica (F.C., Y.H., R.S.), Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Fabian Chablais
- Department of Neurology (V.M., H.H.J.), University Hospital and University of Zurich; and Genetica (F.C., Y.H., R.S.), Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Yvan Herenger
- Department of Neurology (V.M., H.H.J.), University Hospital and University of Zurich; and Genetica (F.C., Y.H., R.S.), Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Roland Spiegel
- Department of Neurology (V.M., H.H.J.), University Hospital and University of Zurich; and Genetica (F.C., Y.H., R.S.), Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| | - Hans Heinrich Jung
- Department of Neurology (V.M., H.H.J.), University Hospital and University of Zurich; and Genetica (F.C., Y.H., R.S.), Human Genetics and Genetic Counselling Unit, Zurich, Switzerland
| |
Collapse
|
6
|
Mueller SM, Mihaylova V, Frese S, Petersen JA, Ligon-Auer M, Aguayo D, Flück M, Jung HH, Toigo M. Satellite cell content in Huntington's disease patients in response to endurance training. Orphanet J Rare Dis 2019; 14:135. [PMID: 31186054 PMCID: PMC6560826 DOI: 10.1186/s13023-019-1115-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 06/04/2019] [Indexed: 12/02/2022] Open
Abstract
Background Skeletal muscle wasting is a hallmark of Huntington’s disease (HD). However, data on myocellular characteristics and myofiber remodeling in HD patients are scarce. We aimed at gaining insights into myocellular characteristics of HD patients as compared to healthy controls at rest and after a period of increased skeletal muscle turnover. Methods Myosin heavy chain (MyHC)-specific cross-sectional area, satellite cell content, myonuclear number, myonuclear domain, and muscle fiber type distribution were determined from vastus lateralis muscle biopsies at rest and after 26 weeks of endurance training in HD patients and healthy controls. Results At the beginning of the study, there were no differences in myocellular characteristics between HD patients and healthy controls. Satellite cell content per MyHC-1 fiber (P = 0.014) and per MyHC-1 myonucleus (P = 0.006) increased significantly in healthy controls during the endurance training intervention, whereas it remained constant in HD patients (P = 0.804 and P = 0.975 for satellite cell content per MyHC-1 fiber and myonucleus, respectively). All further variables were not altered during the training intervention in HD patients and healthy controls. Conclusions Similar skeletal muscle characteristics between HD patients and healthy controls at baseline suggested similar potential for myofiber remodeling in response to exercise. However, the missing satellite cell response in MyHC-1 myofibers following endurance training in HD patients points to a potential dysregulation in the exercise-induced activation and/or proliferation of satellite cells. In the longer-term, impaired myonuclear turnover might be associated with the clinical observation of skeletal muscle wasting.
Collapse
Affiliation(s)
- Sandro Manuel Mueller
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland.,Research and Performance Center for Elite Athleticism, OYM, Lorzenparkstrasse 12, 6330, Cham, Switzerland
| | - Violeta Mihaylova
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Sebastian Frese
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland.,Institute of Human Movement Sciences, ETH Zurich, Zurich, Switzerland
| | - Jens A Petersen
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Maria Ligon-Auer
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - David Aguayo
- Institute of Human Movement Sciences, ETH Zurich, Zurich, Switzerland
| | - Martin Flück
- Department of Orthopaedics, Laboratory for Muscle Plasticity, Balgrist University Hospital, University of Zurich, Zurich, Switzerland
| | - Hans H Jung
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Marco Toigo
- Research and Performance Center for Elite Athleticism, OYM, Lorzenparkstrasse 12, 6330, Cham, Switzerland. .,Institute of Human Movement Sciences, ETH Zurich, Zurich, Switzerland. .,Department of Orthopaedics, Laboratory for Muscle Plasticity, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.
| |
Collapse
|
7
|
Mueller SM, Gehrig SM, Petersen JA, Frese S, Mihaylova V, Ligon-Auer M, Khmara N, Nuoffer JM, Schaller A, Lundby C, Toigo M, Jung HH. Effects of endurance training on skeletal muscle mitochondrial function in Huntington disease patients. Orphanet J Rare Dis 2017; 12:184. [PMID: 29258585 PMCID: PMC5735536 DOI: 10.1186/s13023-017-0740-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 12/07/2017] [Indexed: 12/12/2022] Open
Abstract
Background Mitochondrial dysfunction may represent a pathogenic factor in Huntington disease (HD). Physical exercise leads to enhanced mitochondrial function in healthy participants. However, data on effects of physical exercise on HD skeletal muscle remains scarce. We aimed at investigating adaptations of the skeletal muscle mitochondria to endurance training in HD patients. Methods Thirteen HD patients and 11 healthy controls completed 26 weeks of endurance training. Before and after the training phase muscle biopsies were obtained from M. vastus lateralis. Mitochondrial respiratory chain complex activities, mitochondrial respiratory capacity, capillarization, and muscle fiber type distribution were determined from muscle samples. Results Citrate synthase activity increased during the training intervention in the whole cohort (P = 0.006). There was no group x time interaction for citrate synthase activity during the training intervention (P = 0.522). Complex III (P = 0.008), Complex V (P = 0.043), and succinate cytochrome c reductase (P = 0.008) activities increased in HD patients and controls by endurance training. An increase in mass-specific mitochondrial respiratory capacity was present in HD patients during the endurance training intervention. Overall capillary-to-fiber ratio increased in HD patients by 8.4% and in healthy controls by 6.4% during the endurance training intervention. Conclusions Skeletal muscle mitochondria of HD patients are equally responsive to an endurance-training stimulus as in healthy controls. Endurance training is a safe and feasible option to enhance indices of energy metabolism in skeletal muscle of HD patients and may represent a potential therapeutic approach to delay the onset and/or progression of muscular dysfunction. Trial registration ClinicalTrials.gov NCT01879267. Registered May 24, 2012.
Collapse
Affiliation(s)
- Sandro Manuel Mueller
- Department of Neurology, University Hospital Zurich, , University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Saskia Maria Gehrig
- Department of Neurology, University Hospital Zurich, , University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Jens A Petersen
- Department of Neurology, University Hospital Zurich, , University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Sebastian Frese
- Department of Neurology, University Hospital Zurich, , University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | | | - Maria Ligon-Auer
- Department of Neurology, University Hospital Zurich, , University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Natalia Khmara
- Department of Neurology, University Hospital Zurich, , University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Jean-Marc Nuoffer
- Institute of Clinical Chemistry, University Hospital Bern, Bern, Switzerland
| | - André Schaller
- Division of Human Genetics, University Hospital Bern, Bern, Switzerland
| | - Carsten Lundby
- Institute of Physiology, University of Zurich, Zurich, Switzerland.,Zurich Center for Integrative Human Physiology (ZIHP), Zurich, Switzerland
| | - Marco Toigo
- Laboratory for Muscle Plasticity, Balgrist University Hospital, Department of Orthopaedics, University of Zurich, Zurich, Switzerland.,Institute of Human Movement Sciences, ETH Zurich, Zurich, Switzerland
| | - Hans H Jung
- Department of Neurology, University Hospital Zurich, , University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.
| |
Collapse
|
8
|
Gehrig SM, Petersen JA, Frese S, Mueller SM, Mihaylova V, Ligon-Auer M, Lundby C, Toigo M, Jung HH. Skeletal muscle characteristics and mitochondrial function in Huntington's disease patients. Mov Disord 2017. [PMID: 28620963 DOI: 10.1002/mds.27031] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Saskia Maria Gehrig
- Zurich Center for Integrative Human Physiology, Zurich, Switzerland.,Institute of Physiology, University of Zurich, Zurich, Switzerland.,Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Jens A Petersen
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Sebastian Frese
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | | | - Violeta Mihaylova
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Maria Ligon-Auer
- Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| | - Carsten Lundby
- Zurich Center for Integrative Human Physiology, Zurich, Switzerland.,Institute of Physiology, University of Zurich, Zurich, Switzerland
| | - Marco Toigo
- Institute of Human Movement Sciences and Sport, ETH Zurich, Zurich, Switzerland.,University of Zurich, Balgrist University Hospital, Department of Orthopaedics, Zurich, Switzerland
| | - Hans H Jung
- Zurich Center for Integrative Human Physiology, Zurich, Switzerland.,Department of Neurology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
9
|
Mihaylova V, Jung HH. [Not Available]. Praxis (Bern 1994) 2017; 106:1391-1396. [PMID: 29231087 DOI: 10.1024/1661-8157/a002902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Zusammenfassung. Muskelkrämpfe sind sehr häufig und treten sowohl bei gesunden Menschen als auch im Rahmen von verschiedenen internistischen, rheumatologischen und neurologischen krankhaften Zuständen auf. Muskelkrämpfe bei gesunden Menschen sind selbstlimitierend und in der Regel auf körperliche Überbelastung zurückzuführen. Bei persistierenden, heftigen und therapieresistenten Muskelkrämpfen sollte eine Abklärung durchgeführt werden, wobei hier die Suche nach behandelbaren Ursachen im Vordergrund steht (z.B. mangelhafte Hydratation, muskuläre Überbelastung, Elektrolytverschiebungen, Dysthyreose, Vitaminmangel, Niereninsuffizienz, Leberzirrhose, medikamentös-toxische Nebenwirkungen etc.). Nach Ausschluss solcher symptomatischer Ursachen kann eine neurologische Abklärung zur Suche nach spezifischen neuromuskulären und neurologischen Erkrankungen sinnvoll sein. Primär sollte immer eine kausale Behandlung angestrebt werden. Auch Allgemeinmassnahmen wie Vermeiden krampfauslösender Belastungen, ausreichende Flüssigkeitszufuhr und abendliche Dehnungsübungen sollten instruiert werden. Zur symptomatischen Behandlung von Muskelkrämpfen haben mehrere Medikamente, insbesondere Magnesiumpräparate und Chininsulfat, Wirksamkeit gezeigt. Allerdings stehen keine doppelblinden und Placebo-kontrollierten Studiendaten zur Verfügung.
Collapse
Affiliation(s)
| | - Hans H Jung
- 1 Klinik für Neurologie, Universitätsspital Zürich
| |
Collapse
|
10
|
Gehrig SM, Mihaylova V, Frese S, Mueller SM, Ligon-Auer M, Spengler CM, Petersen JA, Lundby C, Jung HH. Altered skeletal muscle (mitochondrial) properties in patients with mitochondrial DNA single deletion myopathy. Orphanet J Rare Dis 2016; 11:105. [PMID: 27473873 PMCID: PMC4966582 DOI: 10.1186/s13023-016-0488-x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 07/21/2016] [Indexed: 12/13/2022] Open
Abstract
Background Mitochondrial myopathy severely affects skeletal muscle structure and function resulting in defective oxidative phosphorylation. However, the major pathomechanisms and therewith effective treatment approaches remain elusive. Therefore, the aim of the present study was to investigate disease-related impairments in skeletal muscle properties in patients with mitochondrial myopathy. Accordingly, skeletal muscle biopsies were obtained from six patients with moleculargenetically diagnosed mitochondrial myopathy (one male and five females, 53 ± 9 years) and eight age- and gender-matched healthy controls (two males and six females, 58 ± 14 years) to determine mitochondrial respiratory capacity of complex I-V, mitochondrial volume density and fiber type distribution. Results Mitochondrial volume density (4.0 ± 0.5 vs. 5.1 ± 0.8 %) as well as respiratory capacity of complex I-V were lower (P < 0.05) in mitochondrial myopathy and associated with a higher (P < 0.001) proportion of type II fibers (65.2 ± 3.6 vs. 44.3 ± 5.9 %). Additionally, mitochondrial volume density and maximal oxidative phosphorylation capacity correlated positively (P < 0.05) to peak oxygen uptake. Conclusion Mitochondrial myopathy leads to impaired mitochondrial quantity and quality and a shift towards a more glycolytic skeletal muscle phenotype.
Collapse
Affiliation(s)
- Saskia Maria Gehrig
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland.,Institute of Physiology, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.,Zurich Center for Integrative Human Physiology (ZIHP), Winterthurerstrasse 190, 8057, Zurich, Switzerland
| | - Violeta Mihaylova
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Sebastian Frese
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Sandro Manuel Mueller
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Maria Ligon-Auer
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Christina M Spengler
- Zurich Center for Integrative Human Physiology (ZIHP), Winterthurerstrasse 190, 8057, Zurich, Switzerland.,Exercise Physiology Lab, Institute of Human Movement Sciences, ETH Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland
| | - Jens A Petersen
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland
| | - Carsten Lundby
- Institute of Physiology, University of Zurich, Winterthurerstrasse 190, 8057, Zurich, Switzerland.,Zurich Center for Integrative Human Physiology (ZIHP), Winterthurerstrasse 190, 8057, Zurich, Switzerland
| | - Hans H Jung
- Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. .,Zurich Center for Integrative Human Physiology (ZIHP), Winterthurerstrasse 190, 8057, Zurich, Switzerland.
| |
Collapse
|
11
|
Chamova T, Guergueltcheva V, Gospodinova M, Krause S, Cirak S, Kaprelyan A, Angelova L, Mihaylova V, Bichev S, Chandler D, Naydenov E, Grudkova M, Djukmedzhiev P, Voit T, Pogoryelova O, Lochmüller H, Goebel HH, Bahlo M, Kalaydjieva L, Tournev I. GNE myopathy in Roma patients homozygous for the p.I618T founder mutation. Neuromuscul Disord 2015; 25:713-8. [DOI: 10.1016/j.nmd.2015.07.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2015] [Revised: 06/07/2015] [Accepted: 07/07/2015] [Indexed: 02/02/2023]
|
12
|
Mihaylova V, Guergueltcheva V, Cherninkova S, Penev L, Georgieva G, Stoyanova K, Todorova A, Tournev I. Possible toxicity of tuberculostatic agents in a patient with a novel TYMP mutation leading to mitochondrial neurogastrointestinal encephalomyopathy. J Neurogenet 2013; 27:19-22. [PMID: 23590577 DOI: 10.3109/01677063.2013.778256] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare autosomal recessive multisystemic disorder caused by TYMP gene mutations. Here, we report on the first MNGIE patient diagnosed in Bulgaria who carries a novel homozygous TYMP mutation (p.Leu347Pro). The patient presented with gastrointestinal complaints, cachexia, hearing loss, ptosis, ophthalmoparesis, polyneuropathy, cognitive impairment, and leukoencephalopathy on magnetic resonance imaging (MRI) examination of the brain. The patient's motor capacity declined significantly, leading to wheelchair dependence several months following administration of tuberculostatic treatment, suggesting mitochondrial toxicity of these agents. The advanced stage of the disease and the poor medical condition prevented us from performing allogenic hematopoietic stem cell transplantation (HSCT). Early diagnosis is important not only for genetic counseling but also in view of the timely treatment with allogenic HSCT.
Collapse
Affiliation(s)
- Violeta Mihaylova
- Department of Neurology, University Hospital Alexandrovska, 1000 Sofia, Bulgaria.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Guergueltcheva V, Peeters K, Baets J, Ceuterick-de Groote C, Martin J, Suls A, Vriendt E, Mihaylova V, Chamova T, Almeida-Souza L, Ydens E, Tzekov C, Hadjidekov G, Gospodinova M, Storm K, Reyniers E, Bichev S, van der Ven P, Furst D, Mitev V, Lochmuller H, Timmerman V, Tournev I, De Jonghe P, Jordanova A. G.O.7 Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. Neuromuscul Disord 2012. [DOI: 10.1016/j.nmd.2012.06.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Abicht A, Dusl M, Gallenmüller C, Guergueltcheva V, Schara U, Della Marina A, Wibbeler E, Almaras S, Mihaylova V, von der Hagen M, Huebner A, Chaouch A, Müller JS, Lochmüller H. Congenital myasthenic syndromes: Achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: A study of 680 patients. Hum Mutat 2012; 33:1474-84. [DOI: 10.1002/humu.22130] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2011] [Accepted: 04/30/2012] [Indexed: 11/09/2022]
|
15
|
Guergueltcheva V, Peeters K, Baets J, Ceuterick-de Groote C, Martin JJ, Suls A, De Vriendt E, Mihaylova V, Chamova T, Almeida-Souza L, Ydens E, Tzekov C, Hadjidekov G, Gospodinova M, Storm K, Reyniers E, Bichev S, van der Ven PFM, Fürst DO, Mitev V, Lochmüller H, Timmerman V, Tournev I, De Jonghe P, Jordanova A. Distal myopathy with upper limb predominance caused by filamin C haploinsufficiency. Neurology 2011; 77:2105-14. [PMID: 22131542 DOI: 10.1212/wnl.0b013e31823dc51e] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE In this study, we investigated the detailed clinical findings and underlying genetic defect in 3 presumably related Bulgarian families displaying dominantly transmitted adult onset distal myopathy with upper limb predominance. METHODS We performed neurologic, electrophysiologic, radiologic, and histopathologic analyses of 13 patients and 13 at-risk but asymptomatic individuals from 3 generations. Genome-wide parametric linkage analysis was followed by bidirectional sequencing of the filamin C (FLNC) gene. We characterized the identified nonsense mutation at cDNA and protein level. RESULTS Based on clinical findings, no known myopathy subtype was implicated in our distal myopathy patients. Light microscopic analysis of affected muscle tissue showed no specific hallmarks; however, the electron microscopy revealed changes compatible with myofibrillar myopathy. Linkage studies delineated a 9.76 Mb region on chromosome 7q22.1-q35 containing filamin C (FLNC), a gene previously associated with myofibrillar myopathy. Mutation analysis revealed a novel c.5160delC frameshift deletion in all patients of the 3 families. The mutation results in a premature stop codon (p.Phe1720LeufsX63) that triggers nonsense-mediated mRNA decay. FLNC transcript levels were reduced in muscle and lymphoblast cells from affected subjects and partial loss of FLNC in muscle tissue was confirmed by protein analysis. CONCLUSIONS The FLNC mutation that we identified is distinct in terms of the associated phenotype, muscle morphology, and underlying molecular mechanism, thus extending the currently recognized clinical and genetic spectrum of filaminopathies. We conclude that filamin C is a dosage-sensitive gene and that FLNC haploinsufficiency can cause a specific type of myopathy in humans.
Collapse
Affiliation(s)
- V Guergueltcheva
- Department of Neurology, Medical University-Sofia, Sofia, Bulgaria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Mihaylova V, Scola RH, Gervini B, Lorenzoni PJ, Kay CK, Werneck LC, Stucka R, Guergueltcheva V, von der Hagen M, Huebner A, Abicht A, Müller JS, Lochmüller H. Molecular characterisation of congenital myasthenic syndromes in Southern Brazil. J Neurol Neurosurg Psychiatry 2010; 81:973-7. [PMID: 20562457 DOI: 10.1136/jnnp.2009.177816] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To perform genetic testing of patients with congenital myasthenic syndromes (CMS) from the Southern Brazilian state of Parana. PATIENTS AND METHODS Twenty-five CMS patients from 18 independent families were included in the study. Known CMS genes were sequenced and restriction digest for the mutation RAPSN p.N88K was performed in all patients. RESULTS We identified recessive mutations of CHRNE in ten families, mutations in DOK7 in three families and mutations in COLQ, CHRNA1 and CHRNB1 in one family each. The mutation CHRNE c.70insG was found in six families. We have repeatedly identified this mutation in patients from Spain and Portugal and haplotype studies indicate that CHRNE c.70insG derives from a common ancestor. CONCLUSIONS Recessive mutations in CHRNE are the major cause of CMS in Southern Brazil with a common mutation introduced by Hispanic settlers. The second most common cause is mutations in DOK7. The minimum prevalence of CMS in Parana is 0.18/100 000.
Collapse
Affiliation(s)
- V Mihaylova
- Institute of Human Genetics, University of Newcastle upon Tyne, International Centre for Life, Newcastle upon Tyne, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Mihaylova V, Salih MAM, Mukhtar MM, Abuzeid HA, El-Sadig SM, von der Hagen M, Huebner A, Nürnberg G, Abicht A, Müller JS, Lochmüller H, Guergueltcheva V. Refinement of the clinical phenotype in musk-related congenital myasthenic syndromes. Neurology 2009; 73:1926-8. [PMID: 19949040 DOI: 10.1212/wnl.0b013e3181c3fce9] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- V Mihaylova
- Molecular Myology Lab, Friedrich-Baur-Institute, Marchioninistr. 17, 81377 Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Angelicheva D, Tournev I, Guergueltcheva V, Mihaylova V, Azmanov DN, Morar B, Radionova M, Smith SJ, Zlatareva D, Stevens JM, Kaneva R, Bojinova V, Carter K, Brown M, Jablensky A, Kalaydjieva L, Sander JW. Partial epilepsy syndrome in a Gypsy family linked to 5q31.3-q32. Epilepsia 2009; 50:1679-88. [PMID: 19400876 DOI: 10.1111/j.1528-1167.2009.02066.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE The restricted genetic diversity and homogeneous molecular basis of Mendelian disorders in isolated founder populations have rarely been explored in epilepsy research. Our long-term goal is to explore the genetic basis of epilepsies in one such population, the Gypsies. The aim of this report is the clinical and genetic characterization of a Gypsy family with a partial epilepsy syndrome. METHODS Clinical information was collected using semistructured interviews with affected subjects and informants. At least one interictal electroencephalography (EEG) recording was performed for each patient and previous data obtained from records. Neuroimaging included structural magnetic resonance imaging (MRI). Linkage and haplotype analysis was performed using the Illumina IVb Linkage Panel, supplemented with highly informative microsatellites in linked regions and Affymetrix SNP 5.0 array data. RESULTS We observed an early-onset partial epilepsy syndrome with seizure semiology strongly suggestive of temporal lobe epilepsy (TLE), with mild intellectual deficit co-occurring in a large proportion of the patients. Psychiatric morbidity was common in the extended pedigree but did not cosegregate with epilepsy. Linkage analysis definitively excluded previously reported loci, and identified a novel locus on 5q31.3-q32 with an logarithm of the odds (LOD) score of 3 corresponding to the expected maximum in this family. DISCUSSION The syndrome can be classified as familial temporal lobe epilepsy (FTLE) or possibly a new syndrome with mild intellectual deficit. The linked 5q region does not contain any ion channel-encoding genes and is thus likely to contribute new knowledge about epilepsy pathogenesis. Identification of the mutation in this family and in additional patients will define the full phenotypic spectrum.
Collapse
Affiliation(s)
- Dora Angelicheva
- Laboratory for Molecular Genetics, Centre for Medical Research and Western Australian Institute for Medical Research, The University of Western Australia, Perth, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Sivadorai P, Cherninkova S, Bouwer S, Kamenarova K, Angelicheva D, Seeman P, Hollingsworth K, Mihaylova V, Oscar A, Dimitrova G, Kaneva R, Tournev I, Kalaydjieva L. Genetic heterogeneity and minor CYP1B1 involvement in the molecular basis of primary congenital glaucoma in Gypsies. Clin Genet 2008; 74:82-7. [PMID: 18537981 DOI: 10.1111/j.1399-0004.2008.01024.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Primary congenital glaucoma (PCG) is a genetically heterogeneous disorder of autosomal recessive inheritance, with mutations in the cytochrome P450 1B1 (CYP1B1) gene detected in an average of approximately 50% of cases worldwide. The Roma/Gypsies are considered to be a rare example of a single founder CYP1B1 mutation, E387K (identified in the Slovak Roma), accounting for 100% of disease alleles. Contrary to this concept, unusual genetic heterogeneity was revealed in this study of 21 Gypsy PCG patients from Bulgaria and 715 controls from the general Gypsy population. In our small sample of affected subjects, we identified five different CYP1B1 mutations - four known (E229K, R368H, E387K and R390C) and one novel and potentially pathogenic (F445I), which together accounted for approximately 30% of disease alleles. E387K was rare in both the patient and the control group, indicating that its high frequency in the Slovak Roma is the product of local founder effect not representative of the overall molecular pattern of PCG in the Gypsy population. Data on other Mendelian disorders and on the population genetics of the Gypsies suggest that a true founder mutation is likely to exist and has remained undetected. Our analysis of another candidate gene, MYOC, and the GLC3B and GLC3C loci did not provide support for their involvement. The molecular basis of PCG in the Gypsies is thus unresolved, and diagnostic analyses should be extended beyond the E387K mutation.
Collapse
Affiliation(s)
- P Sivadorai
- Laboratory of Molecular Genetics, Western Australian Institute for Medical Research, Centre for Medical Research, The University of Western Australia, Perth, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Mihaylova V, Müller T, Petrova I, Tournev I, Cherninkova S, Walter MC, Deschauer M. Unique PABPN1 gene mutation in a large Bulgarian family with OPMD. J Neurol 2008; 255:609-11. [DOI: 10.1007/s00415-008-0769-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2007] [Revised: 09/19/2007] [Accepted: 10/05/2007] [Indexed: 11/30/2022]
|
21
|
Mihaylova V, Müller JS, Vilchez JJ, Salih MA, Kabiraj MM, D’Amico A, Bertini E, Wölfle J, Schreiner F, Kurlemann G, Rasic VM, Siskova D, Colomer J, Herczegfalvi A, Fabriciova K, Weschke B, Scola R, Hoellen F, Schara U, Abicht A, Lochmüller H. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008; 131:747-59. [DOI: 10.1093/brain/awm325] [Citation(s) in RCA: 107] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Nascimento A, Colomer J, Fons C, Müller J, Mihaylova V, Jimenez-Mallabrera C, Lochmüller H. G.P.10.08 Fetal myasthenia and arthrogryposis multiplex congenita caused by mutation in the fetal γ-subunit of the acetylcholine receptor (CHRNG): Escobar syndrome. Neuromuscul Disord 2007. [DOI: 10.1016/j.nmd.2007.06.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
23
|
Mihaylova V, Todorov T, Jelev H, Cherninkova S, Raycheva M, Savov A, Kremensky I, Tournev I. Wilson’s disease in two consecutive generations in a Bulgarian Roma family. J Neurol 2007; 254:1462-3. [PMID: 17694349 DOI: 10.1007/s00415-007-0564-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2006] [Revised: 12/17/2006] [Accepted: 01/11/2007] [Indexed: 11/25/2022]
|
24
|
Abstract
The neuromuscular junction (NMJ) is a complex structure that efficiently communicates the electrical impulse from the motor neuron to the skeletal muscle to induce muscle contraction. Genetic and autoimmune disorders known to compromise neuromuscular transmission are providing further insights into the complexities of NMJ function. Congenital myasthenic syndromes (CMSs) are a genetically and phenotypically heterogeneous group of rare hereditary disorders affecting neuromuscular transmission. The understanding of the molecular basis of the different types of CMSs has evolved rapidly in recent years. Mutations were first identified in the subunits of the nicotinic acetylcholine receptor (AChR), but now mutations in ten different genes - encoding post-, pre- or synaptic proteins - are known to cause CMSs. Pathogenic mechanisms leading to an impaired neuromuscular transmission modify AChRs or endplate structure or lead to decreased acetylcholine synthesis and release. However, the genetic background of many CMS forms is still unresolved. A precise molecular classification of CMS type is of paramount importance for the diagnosis, counselling and therapy of a patient, as different drugs may be beneficial or deleterious depending on the molecular background of the particular CMS.
Collapse
Affiliation(s)
- Juliane S Müller
- Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, Munich, Germany
| | | | | | | |
Collapse
|
25
|
Müller JS, Herczegfalvi A, Vilchez JJ, Colomer J, Bachinski LL, Mihaylova V, Santos M, Schara U, Deschauer M, Shevell M, Poulin C, Dias A, Soudo A, Hietala M, Aärimaa T, Krahe R, Karcagi V, Huebner A, Beeson D, Abicht A, Lochmüller H. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007; 130:1497-506. [PMID: 17439981 DOI: 10.1093/brain/awm068] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Dok ('downstream-of-kinase') family of cytoplasmic proteins play a role in signalling downstream of receptor and non-receptor phosphotyrosine kinases. Recently, a skeletal muscle receptor tyrosine kinase (MuSK)-interacting cytoplasmic protein termed Dok-7 has been identified. Subsequently, we and others identified mutations in DOK7 as a cause of congenital myasthenic syndromes (CMS), providing evidence for a crucial role of Dok-7 in maintaining synaptic structure. Here we present clinical and molecular genetic data of 14 patients from 12 independent kinships with 13 different mutations in the DOK7 gene. The clinical picture of CMS with DOK7 mutations is highly variable. The age of onset may vary between birth and the third decade. However, most of the patients display a characteristic 'limb-girdle' pattern of weakness with a waddling gait and ptosis, but without ophthalmoparesis. Respiratory problems were frequent. Patients did not benefit from long-term therapy with esterase inhibitors; some of the patients even worsened. DOK7 mutations have emerged as one of the major genetic defects in CMS. The clinical picture differs significantly from CMS caused by mutations in other genes, such as the acetylcholine receptor (AChR) subunit genes. None of the patients with DOK7 mutations had tubular aggregates in the muscle biopsy, implying that 'limb-girdle myasthenia (LGM) with tubular aggregates' previously described in literature may be a pathogenic entity distinct from CMS caused by DOK7 mutations.
Collapse
MESH Headings
- Adolescent
- Adult
- Biopsy
- Child
- Child, Preschool
- Cholinesterase Inhibitors/adverse effects
- Cholinesterase Inhibitors/therapeutic use
- DNA Mutational Analysis/methods
- Electric Stimulation
- Female
- Gait Disorders, Neurologic/genetics
- Humans
- Male
- Middle Aged
- Muscle Proteins/genetics
- Muscle, Skeletal/pathology
- Muscular Dystrophies, Limb-Girdle/drug therapy
- Muscular Dystrophies, Limb-Girdle/genetics
- Muscular Dystrophies, Limb-Girdle/pathology
- Mutation
- Myasthenic Syndromes, Congenital/drug therapy
- Myasthenic Syndromes, Congenital/genetics
- Myasthenic Syndromes, Congenital/pathology
- Phenotype
- Polymorphism, Restriction Fragment Length
- Treatment Failure
Collapse
Affiliation(s)
- Juliane S Müller
- Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University, Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Mihaylova V, Hantke J, Sinigerska I, Cherninkova S, Raicheva M, Bouwer S, Tincheva R, Khuyomdziev D, Bertranpetit J, Chandler D, Angelicheva D, Kremensky I, Seeman P, Tournev I, Kalaydjieva L. Highly variable neural involvement in sphingomyelinase-deficient Niemann-Pick disease caused by an ancestral Gypsy mutation. Brain 2007; 130:1050-61. [PMID: 17360762 DOI: 10.1093/brain/awm026] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Niemann-Pick disease (NPD), an autosomal recessive disorder resulting from mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene, is subdivided into the acute, lethal neuronopathic type A, and the chronic visceral type B, explained by the different residual activity levels of acid sphingomyelinase (ASMase). An increasing number of reports on intermediate forms, challenging this traditional clinical classification, have described a broad range of neurological manifestations; however genotype-phenotype correlations have been compromised by relatively small sample sizes and/or allelic heterogeneity. Here we present a genetically homogeneous group of 20 Gypsy patients with intermediate NPD, where we observed a surprising diversity of neurological features. All affected subjects were homozygous for the same ancestral mutation, W391G in SMPD1, yet displayed the entire spectrum of phenotypic variation observed previously in unrelated affected subjects of diverse ethnicity and disease-causing mutations, ranging from subclinical retinal involvement to severe ataxia, cognitive deficits and psychiatric disorders. The clinical heterogeneity of W391G homozygotes points to additional factors, beyond SMPD1 and residual ASMase, which determine the localization, extent and severity of neural involvement. The phenotype similarity of affected relatives suggests a possible role of genetic modifying factors. In practical terms, W391 is common in the Gypsy population and the diagnosis of NPD should be borne in mind despite the atypical course of the disease. Generally, our findings indicate that mutation analysis is of limited value in predicting brain damage, and the option of enzyme replacement therapy should be considered in intermediate NPD.
Collapse
|
27
|
Todorov T, Savov A, Mihaylova V, Buettner J, Koseva O, Krustev Z, Jelev H, Tournev I, Penkov V, Konstantinova D, Tankova L, Tzolova N, Kremensky I, Schmidt H. Ethnic specific background of mutations in Bulgarian patients with Wilson disease. Genet Couns 2007; 18:445-450. [PMID: 18286826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
|
28
|
Chakarova CF, Cherninkova S, Tournev I, Waseem N, Kaneva R, Jordanova A, Veraitch BK, Gill B, Colclough T, Nakova A, Oscar A, Mihaylova V, Nikolova-Hill A, Wright AF, Black GCM, Ramsden S, Kremensky I, Bhattacharya SS. Molecular genetics of retinitis pigmentosa in two Romani (Gypsy) families. Mol Vis 2006; 12:909-14. [PMID: 16917484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023] Open
Abstract
PURPOSE To identify the disease-causing mutations in two large Bulgarian Romani (Gypsy) pedigrees: one with autosomal dominant retinitis pigmentosa (adRP) with partial penetrance and the other with severe X-linked RP (xlRP). METHODS Detailed clinical investigations were undertaken and genomic DNA was extracted from blood samples. DNA was analyzed by PCR amplification with gene-specific primers and direct genomic sequencing. RESULTS Analysis of the complete coding sequence of PRPF31 in the adRP family led to the identification of a new heterozygous splice site mutation IVS6+1G>T. RPGR mutation screening in affected male individuals in the X-linked RP family identified a hemizygous c.ORF15+652_653delAG mutation. Interestingly this mutation was found in a homozygous state in one severely affected female from the family. CONCLUSIONS In this first report of molecular genetic analysis of retinitis pigmentosa in Romani families, we describe a novel PRPF31 mutation and present the first case of a homozygous mutation in the RPGR gene in a female individual.
Collapse
|
29
|
Mihaylova V, Todorov T, Tournev I, Cherninkova S, Nikoevski N, Raicheva M, Iankova P, Petrova I, Savov A, Kremesky I. A Novel Mutation in ATP7B Gene Associated with Severe Neurological and Psychiatric Symptoms. Eur Neurol 2006; 55:99-100. [PMID: 16636554 DOI: 10.1159/000092783] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2005] [Accepted: 01/13/2006] [Indexed: 11/19/2022]
|
30
|
Todorov T, Savov A, Jelev H, Panteleeva E, Konstantinova D, Krustev Z, Mihaylova V, Tournev I, Tankova L, Tzolova N, Kremensky I. Spectrum of mutations in the Wilson disease gene (ATP7B) in the Bulgarian population. Clin Genet 2005; 68:474-6. [PMID: 16207219 DOI: 10.1111/j.1399-0004.2005.00516.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Mihaylova V, Liotchkova M. Psychosocial problems in elderly subjects from geriatric home revitalization approach. Folia Med (Plovdiv) 1999; 41:104-7. [PMID: 10462936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
The psychosocial aspects of aging and senility appear a major problem for the marked senescence of the Bulgarian nation--25% of the population is over the age of 60 years. The present study attempts to make a medico-ethic and social evaluation of life quality in old age and illness and outline possibilities for appropriate revitalization of elderly subjects dwelling geriatric homes. The governing body of the geriatric home does not refer to scientific methods of management for planning and organization of everyday living activities. No coping strategy is applied to reduce stress and illness offence. Current scientific revitalization approach should be realized in the policy of the geriatric home to prevent a long-term disabled existence and induce a worthier lifestyle.
Collapse
Affiliation(s)
- V Mihaylova
- Department of Social Medicine, Higher Medical Institute, Plovdiv, Bulgaria
| | | |
Collapse
|